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Abstract
Background: Trials have become bigger and more complicated due to the complexity introduced by biomarker
stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials
unit at University College London has been at the forefront of this work, with ground-breaking trials such as
STAMPEDE and FOCUS4. The trial management and data management teams on these trials have summarised the
operational challenges, to enable the broader clinical trials community to learn from their experiences. In a small-
scale qualitative study, we examined the personal experience of individual researchers working on these trials.
Commentary: We found reports of high workloads, with potentially significant stress for individuals and with an
impact on their career choices. We conclude that there was an initial underestimation of the work required and of
the inherent, largely unanticipated, challenges. We discuss the importance of fully understanding these trials’
resource requirements, both for those writing grant applications and critically, for those with responsibility for
deciding on funding.
The working environment was characterised by three features: complexity, scale and heightened expectations.
These features are highly attractive for professional development and engender high levels of loyalty and
commitment. We observed a trade-off between these intrinsic rewards and the continuous demands of
overlapping tasks, balancing a mix of routine and high-profile work, and the changing nature of pivotal roles. Such
demands present challenges for colleague relationships, by enhancing the potential for competition and by
disrupting the natural opportunities to pause, review and celebrate team achievements. In addition, molecular
stratification in effect brings the patient into the trial office, as a specific individual, despite anonymisation, who is
owed test results and a treatment decision. We discuss these observations with a view to interconnecting the need
for compassion for patients with caring for the researchers engaged in the research ecosystem who are aiming to
produce much hoped-for advances in medical science.
Conclusions: There is a need for increased awareness of the challenge these studies place on those throughout
the team delivering the study. Such considerations must influence leaders and funders, both in their initial budget
considerations and throughout delivery.
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Background
Clinical trials in the 21st century are evolving from the
traditional two-arm comparison of an experimental
treatment vs. a control, to accelerate identification of
promising therapies, to increase throughput and to allow
for the increasing use of molecular classification of pa-
tients into smaller sub-groups [1]. ‘Platform protocols’ is
a broad descriptor of protocols that allow for the simul-
taneous evaluation of multiple treatments within at least
one disease area, in some cases against a common control
[2, 3]. (The term ‘master protocol’ may also be used [3];
here we use the term ‘platform protocols’ for consistency
with the papers that provoked this work.) Such trial types
may also be adaptive in design—such as the multi-arm,
multi-stage platform design—whereby pre-planned in-
terim analyses allow interventions with little evidence of
benefit to be terminated quickly and new arms to be
added as further technologies emerge [1, 4]. The adding
and dropping of arms from a protocol is an important
feature of the efficiency of the design, but it adds substan-
tial complexity to the operational delivery of a study. As
these approaches are relatively new, there is as yet limited
research literature on the operational challenges of these
more complex trial designs.
The Medical Research Council’s Clinical Trials Unit at
University College London (UCL) has been at the fore-
front of developing and implementing such platform pro-
tocols. In the accompanying two papers, researchers share
their observations on the operational challenges of such
trials, to enable the broader clinical trials community to
learn from their experiences. Schiavone et al. describe the
experiences of the trial managers [5], while Hague et al.
write from the perspective of data management [6].
In this commentary, we provide an additional perspec-
tive to their observations by exploring the human ex-
perience of the researchers working on these complex
trials. In a small-scale qualitative project, we examined
the effect on individuals, their lives, their careers and
their job satisfaction. This work stems from the interest
of three of the authors (LM, JH and TSM) in the societal
significance of the precision medicine paradigm [7, 8]
working with a diverse group encompassing clinicians,
psychologists, patient advocates, health economists, ethi-
cists and theologians. We have applied the broad per-
spective of that group in considering the implications
here, drawing on a project of the Oxford Healthcare
Values Partnership entitled Compassion in healthcare:
practical policy for civic life, which considered not only
the role of compassion in relationships between clini-
cians and patients [9] but also the care offered to col-
leagues and teams working in healthcare [10].
We emailed researchers at a single unit to invite par-
ticipation, with no follow-up and no compulsion. We
acknowledge that the individuals attracted by this
light-touch recruitment approach may not be fully repre-
sentative, but our main concern was to encourage an
open conversation and to establish the independence of
the interviewer from the unit’s management. The inter-
views were minimally structured. Each discussion was
deliberately left open to follow the issues raised by the
interviewee, rather than following a structured discus-
sion guide with specific questions predefined by the
interviewer. Altogether, 18 researchers volunteered to
speak to us, resulting in over 15 h of recorded and
transcribed interviews. We used the recordings, inter-
view notes and transcripts to identify key topics. Infor-
mation from the interviews was extracted into a grid
under these headings, which were grouped into over-
arching themes.
As the discussions covered potentially sensitive topics,
we committed to preserve the anonymity of all partici-
pants. For this reason, combined with the small scale of
the study, we share our observations here as a summary
overview. Our observations are organised under four
main themes: we link to the findings in the UCL papers,
and provide commentary on implications for individuals,
trials units and funders.
Efficiency
I think I, at least, underestimated the work that was
involved, to begin with.
For the readership of Trials, there is no need to
rehearse the expected methodological efficiencies of
platform protocols. What we and the trials unit found,
though, was that the central resources needed to achieve
the practical efficiencies were greater than expected,
when the trials expanded. Schiavone et al. describe the
work involved in adding a new comparison by amending
an existing protocol [5]. Hague et al. discuss the work
involved in changing the database to accommodate add-
itional comparisons without impacting the ever-growing
data from ongoing comparisons [6]. Both papers note
the additional work entailed in trials involving biomarker
stratification.
The impact for individuals of the resulting unantici-
pated activities is a high workload, leading to a sense of
not being in control. Importantly, there is an impact on
individuals’ career choices, particularly with regard to
part-time working:
It’s just never enough.
This is not a job you could do part time.
Whilst workloads were reported to have reduced as
the understanding of resource needs improved, there
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was an inevitable lag, due to limited flexibility to in-
crease funding mid-grant. It is, therefore, essential to im-
prove our understanding of the resource requirements
of platform protocols for those writing grant applica-
tions, but perhaps even more importantly, for those re-
sponsible for reviewing them and making funding
decisions. The two UCL papers make a valuable contri-
bution to this discussion.
For trials units and lead investigators, a keen awareness
of the staffing required to meet the repeated set-up and
data management activities will help to calibrate the budget
setting process. Contributions from commercial partners
may also be challenging to quantify, as it is very rare for
contracts to be signed and for funding to be agreed prior
to grant submission. Over-optimism regarding commercial
contributions is a real danger, as partners are prepared to
contribute free drugs and distribution costs often only until
they see a clear line of sight for commercial development.
These factors can be very difficult to predict, so flexibility
around the funding of such treatments is likely required,
which can be challenging to administer and agree.
Further, investigators and funders can benefit from
engagement with patient representatives both at the
proposal stage and throughout the life of the trial. The
trials discussed here have active patient representatives.
It may be that the questions posed to patient and pub-
lic involvement representatives need some reconsider-
ation to ensure that there is a focus on the things that
really matter.
Reassuringly, issues of workload are inherently manage-
able once resource needs are understood. Our remaining
themes characterise the nature of that work and its impact
on individuals and the working environment.
Complexity
We’re doing all of the life cycle of a normal trial—but
all within the same time point.
Both UCL papers refer to the parallel workload of run-
ning multiple trial arms that are at different stages in the
life cycle of a trial [5, 6]. Although from a trials unit per-
spective it is usual to have multiple trials at different
stages, in a platform protocol, this breadth is more likely
to be experienced by an individual. For researchers, this
creates challenging and fast-paced work, and exciting
career development opportunities. Within a short
period, a researcher can be exposed to, and gain experi-
ence in, all stages of a trial:
I got the experience in five years—even I guess in less
than five years—of what some [researchers] wouldn’t
get in ten years.
Anything else would be really simple. I’d maybe be a
bit bored.
However, individuals also have to manage multiple
overlapping tasks and continually need to make priority
choices. In particular, staff noted the conflict between
day-to-day tasks and higher-profile work, like opening
new arms, with limited flexibility to adjust time points
for activities specified by the adaptive design:
It’s the fact that you've got to do that in parallel with
the start of new trials, and collecting data from the
arms that have been running for years all at the same
time.
The continual demand from different tasks disrupts
the normal peaks and troughs in work and obscures the
natural points at which a team can pause, celebrate and
mark progress, and reflect:
There is never a point where you say, ‘And we're done.’
It's always: ‘OK what’s the next move?’
To prevent these necessary breakpoints from becom-
ing submerged and lost, trials units need to develop con-
scious mechanisms to identify such key points, so that
teams can mark their progress and acknowledge the ef-
fort taken to achieve it.
With so many exciting career opportunities, we
observed a potential for turf conflict, highlighting the
importance of the clear and transparent allocation of
tasks. However, it is important that trials units do not
respond by narrowing roles, such as by asking individ-
uals to focus on a particular type of task. Whilst some
clarification of roles is helpful, this needs to be balanced
against maintaining the challenges and career develop-
ment opportunities that researchers find so stimulating
in these trials:
There’ll be one or two data managers who are just
doing data entry. … That’s not necessarily a great job
to have 100% of your time.
Scale
I was the first ever ‘third data manager’.
As these trials have grown, so have the trials unit
teams. Schiavone et al. comment on the need for larger
central teams [5]; Hague et al. discuss the impact of
scale on database design and structure [6]. Both note
that the expanded scale applies to longevity as well as
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people, and combined with the large number of trial
sites, creates added demand for ongoing training:
Say you’ve got 100 sites, and you’ve got maybe two
people that can do data entry. And out of those, some
of them are going to be leaving that year, … so then
you’ve got to train up the next person.
Whilst issues of scale are not unique to platform pro-
tocols, they clearly affect the nature of the work. For a
trials unit, the project management challenges presented
by these large trials are considerable at all levels, includ-
ing senior leadership. Even able and committed chief
investigators and clinical leads are unlikely to have re-
ceived the training and support required to equip them
for a general management role that is potentially equiva-
lent to that of a chief executive officer of a medium-
sized company.
Importantly, the expanded project scale significantly
changes the role of the data manager, and perhaps even
more so, the clinical trial manager, from being a central
contact point with sole responsibility for all aspects of a
trial to being one member of a team. This can create
challenges in maintaining the motivation of individuals,
who may feel that their role has been diminished and is
less satisfying, or feel a loss of ownership for a trial they
are working on:
Once you’ve got more trial managers, their centrality is
lost.
In addition to supporting the current staff in adjusting
to their changed role, trials units may need to revise em-
ployment criteria to ensure that new trial managers have
clear expectations and a good skill fit for the new role.
Hype
I love that study. It’s a great trial.
This theme relates to the effect of working on
high-profile successful trials considered groundbreaking
in some way. For one of the trials, part of the potential
hype was the current high profile of personalised medi-
cine, whilst for the others it was the novelty, scale and
successful history of the project.
The result for individual researchers is a strong attach-
ment to these trials, because of their novelty, the
cutting-edge science, the intellectual challenge and their
potential to benefit patients:
It’s quite motivating, the fact that we are quite a
flagship trial and it has changed standard of care.
This is the first time I’m doing something that I would
say was really exciting.
These attachments created a sense of commitment
and loyalty, in a range of different ways: loyalty to
patients who are waiting for biomarker results, to the
history and success of the trial, and to good science
through generating quality results and meeting the com-
mitments declared in the protocols, to funders and to
regulators. The sense of loyalty adds to the demands that
individuals experience in working on these trials,
particularly if the trial is highly visible:
I never want to be the person who’s got it stuck with
me.
It has to look like it’s going well.
Notably, the biomarker-stratified trial has the effect of
making staff in the trial office aware of specific patients
in a unique way compared to non-stratified trials.
Despite anonymization, there is, nonetheless, a sense of
the trial being about specific individuals who are owed
individualised test results and treatment decisions. This
sense of engagement with patients was shared by the
laboratory, who see first-hand how few patients are actu-
ally eligible for targeted treatment:
We are very aware of the numbers. The numbers of
patients who go out with kind of a good news report
and then others who go out with a ‘Sorry. We haven’t
found anything that’s going to change your treatment.’
Within the trials unit, the hype can impact researchers
working on other trials. When flagship trials received
internal recognition or external publicity, some com-
mented on the negative reactions from staff not involved
with the trial and the demotivating effect on colleagues
when “other great things … didn’t get as much airtime.”
There used to be—not kind of audible groan, but
whenever it was talked about some people then were
like: Oh, [trial] again ….
Overall, in addition to the work that has to be done
(known as extrinsic demand in the literature on work-
place stress [11]), the sense of hype surrounding these
high-profile trials appeared to strengthen the intrinsic
demand stemming from the motivation of the individual.
This presents a challenge for the leadership of trials
units in protecting the well-being of researchers on these
trials without blunting their commitment, and at the
same time, sustaining motivation for those working on
less high-profile trials.
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Compassion and care
Schiavone et al. and Hague et al. provide practical sug-
gestions for addressing the operational challenges of
platform trials. Here we approach the findings from a
different angle, that of compassion and care, which
raises questions about the ethos of platform protocols.
Previous work has paid attention to the interrelation
between compassion and risk in the ethos of stratified
medicine in general, with a particular focus on the inter-
relation between patients and clinicians [9], and caring for
colleagues and teams working in healthcare more gener-
ally [10]. Here, the more delimited focus is on the context
of a trials unit as a context for compassion and care.
First, the phenomenon noted above in the context of
biomarker-driven trials, whereby staff in the trial office
become aware of the treatment options for specific pa-
tients, (albeit anonymised), has significantly reduced the
emotional distance between patients and researchers,
making a somewhat attenuated kind of individualised
compassion possible. Researchers feel the urgency of
their duty to attend to a test speedily and return the re-
sults. Their work draws them into the needs of individ-
ual patients and thus, into a kind of personalised
relationship. However, this relationship lacks meaning-
ful access to the normal bases of compassion in clin-
ician–patient relationships (e.g. the patient’s
background, life journey and what is important to them
at this point), which make possible a rich, interpersonal
experience.
The challenge for those working in a trial setting is
that the incipient compassion they may feel—albeit
anonymised with no name, face or story to attach to the
assay—is contextualised by the trial team’s overall aware-
ness of the numbers of patients involved. The trial team
have insight both into the lack of therapeutic options for
the majority of patients and thus, the likely gravity of the
consequences for many individuals. This experience
regarding individual patients indicates that trial teams
should consider how to support researchers over the
long term if results that indicate targeted therapeutic op-
tions are relatively infrequent while optimism remains
high.
The challenge is how the reduced emotional distance
between bench and bedside, which lacks the face-to-face
quality of clinical relationships, can nonetheless enhance
the compassionate sense of purpose, which researchers
may see as key to their sense of vocation. A way to ad-
dress this would be to bring elements of the ongoing
narratives of anonymised patients being served by the
trial team—whether those patients have been eligible for
targeted treatments or not—into team meetings, provid-
ing more of a sense of how the trial team’s work is inter-
acting with real life stories. Twice yearly meetings at
which research nurses involved in trial delivery at trial
sites share such participant stories with the overall team
could accomplish this and enhance the research nurses
understanding of the trials unit’s needs, to the mutual
benefit of both parties. This approach would be a sensi-
tive complement to the increasingly common practice of
involving patient representatives in the design stage of
trials and throughout a trial’s lifetime, as noted earlier.
Second, notwithstanding that working on a trial with a
platform protocol can be exciting and career-enriching,
staff reports of the significant difficulties and stresses of
such work call for reflection on what caring for re-
searchers’ well-being might entail. In particular, the chal-
lenges of scale and complexity alongside a built-in and
progressive reduction in moments for rest or celebration
disrupt the opportunities for the trial to be experienced
as a shared journey, a narrative that would facilitate staff
members’ self-care and care for each other. Similarly, a
drive for efficiency that narrows staff experience and
opportunities may lead to demoralisation and fragmen-
tation rather than collegiality. Accordingly, identifying
those key points where teams can share their common
achievements and disappointments should also afford
opportunities for the stresses and strains on teams and
individuals to be acknowledged and engaged with.
This process is particularly important because of the
loyalty that trial team members have articulated towards
the trials they are involved in, especially to the history of
the trial and thus, the fear of its failing to achieve the
hoped-for patient benefits. Caring for staff will require
acknowledging the emotional costs to researchers of this
level of commitment. After considering our interviewees’
overall attitudes to these trials, we found that their
strong attachment and motivation conflicts with the
chronically high demands on their time and energy.
Such committed, loyal researchers may be less likely to
consider or talk about their own well-being and there-
fore, less likely to access support or raise concerns.
Practical issues for teams to consider include creative
role management, careful engagement with line man-
agers and human resources personnel, and career coun-
selling. A caring ethos for such trials would require that
loyalty to the shared hope in a trial’s future promise does
not trump the needs of colleagues in the present.
Conclusions
Complex, adaptive studies with the added challenge of
molecular stratification are essential for driving forward
a new era in clinical trials, particularly in precision
medicine. They represent a form of collaborative science
in which clinicians, statisticians, biomarker laboratory
scientists, trial managers and data managers all play a
critical role. Leading such enterprises, for both chief
investigators and trials unit leads, can be demanding and
time-consuming, and yet little is being done to train or
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prepare such individuals. Awareness of patient perspectives
through end-to-end engagement with patient representa-
tives is now expected as standard. In addition, there should
also be increased awareness of the challenge such studies
place on everyone in the team delivering the study. Ensur-
ing that researchers’ connection with patient perspectives
and narratives, and with each other’s experience in the trial,
are vital elements of a compassionate and caring trial en-
vironment. These considerations must influence leaders
and funders, both in their initial budget considerations and
in the long haul of delivery for such exciting research.
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